Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Choroidal Thickness Association With Primary Angle Closure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03050073
Recruitment Status : Completed
First Posted : February 10, 2017
Last Update Posted : August 10, 2018
Sponsor:
Information provided by (Responsible Party):
Groupe Hospitalier Paris Saint Joseph

Brief Summary:
A chinese study shows that chinese population eyes with a primary angle closure have a greater choroidal thickness than normal eyes.The increase of choroidal thickness would be associated to this primary angle closure.

Condition or disease
Choroidal Thickness

Detailed Description:
Usual ophtalmic consultation for glaucoma with primary angle closure

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 42 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 30 Days
Official Title: Choroidal Thickness Association With Primary Angle Closure
Actual Study Start Date : April 18, 2016
Actual Primary Completion Date : June 30, 2016
Actual Study Completion Date : December 31, 2016



Primary Outcome Measures :
  1. change of choroidal thickness measurement by Imaging of the fundus oculi (OCT swept source) [ Time Frame: Day 1 Day 30 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Every patient consulting for glaucoma or not with primary angle closure
Criteria

Inclusion Criteria:

  • Age >18 years
  • Primary angle closure confirmed by gonioscopy
  • interpretable images for choroidal thickness measure
  • interpretable images by Ultra Bio Microscopy (UBM)

Exclusion Criteria:

  • Acute crisis for angle closure
  • Rethinopathy (diabetic or hypertensive)
  • Histories of intra-eye surgery
  • Great myopia
  • Hypermetropia
  • retinal pathology

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03050073


Locations
Layout table for location information
France
Groupe Hospitalier Paris Saint Joseph
Paris, Ile-de-France, France, 75014
Sponsors and Collaborators
Groupe Hospitalier Paris Saint Joseph
Investigators
Layout table for investigator information
Study Director: Hélène BEAUSSIER, Pharm-D CRC
Additional Information:

Layout table for additonal information
Responsible Party: Groupe Hospitalier Paris Saint Joseph
ClinicalTrials.gov Identifier: NCT03050073    
Other Study ID Numbers: IRIS
First Posted: February 10, 2017    Key Record Dates
Last Update Posted: August 10, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No